EW Weekly, May 24, 2019

- Phase 3 glaucoma therapy from Ocular Therapeutix fails to meet endpoint
- Researchers: Glaucoma patients may be at higher risk of vehicle accidents
- Accelerated development for Orion Visual Cortical Prosthesis System planned
- Clinical hold lifted on ADVM-022 in Phase 1 trial for wet AMD
- IncobotulinumtoxinA approved for blepharospasm in adults
- Providers spend more time using an electronic health record (EHR) for an office visit and generate longer notes, according to Isaac Goldstein, BA, and fellow researchers, in their single-cohort study on how documentation behaviors have changed 10 years after EHR adoption. A total of 685,361 office visits among 70 ophthalmology providers were analyzed. The mean EHR time per office visit in 2006 was 4.2 minutes, which increased to 6.4 minutes in 2016. The median note length was 1,530 characters in 2006 compared with 3,838 characters in 2016. Median chart closure time was 2.8 hours in 2006, which lowered to 2.3 hours in 2016. A redesign of EHRs and new documentation regulations may help address these issues, the researchers concluded. The study appears in Ophthalmology.
- Timolol, latanoprost, and travoprost alone or medications that contain timolol as an additional active substance have a good relative IOP-lowering effect after uncomplicated cataract surgery, reported J. L. Holm and coresearchers. Their systematic review analyzed the literature regarding prophylactic treatment of IOP elevation after cataract surgery. They found 23 randomized controlled trials and one nonrandomized controlled study with a total of 45 treatment arms and 14 different active substances in their qualitative synthesis. Nine trials were graded as high quality, 12 as moderate quality, and three as low quality. The primary outcomes for the review were absolute and relative pressure-lowering effect of the drugs after 3 to 8 hours and 1 day postop. The trials showed a relative effect from 18.6% to 29.6% at 3 to 8 hours and 9.8% to 23.6% at day 1. The study is published in Acta Ophthalmologica.
- Selective laser capsulotomy using a new proprietary trypan blue formulation was safe and effective in cataract surgery, reported Pavel Stodulka, MD, and coresearchers. They focused on anterior capsulotomy creation with the CAPSULaser device (Excel-Lens) against those of manual capsulotomies. Patients were divided into cohorts based on age and cataract grade and randomly allocated for laser capsulotomy or continuous curvilinear capsulorhexis, and the anterior capsule was stained with microfiltered trypan blue 0.4%. The anterior capsulotomy was created with the laser device focused on the anterior capsule via a custom patient interface lens. There were no intraop complications. In the laser group, all capsulotomies were free-floating, with no tags or tears. The mean capsulotomy diameter was 5.03 mm overall. All capsulotomies in the laser group were within 0.1 mm of the target. Circularity accuracy was greater than 99%, and the mean centration of the capsulotomy in relation to the IOL was 0.1 mm. All parameters were statistically significant (P<.01). The study appears in the Journal of Cataract & Refractive Surgery.
This issue of EyeWorld Weekly was edited by Stacy Jablonski and Vanessa Caceres.
EyeWorld Weekly (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery (ASCRS), is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, Chief Medical Editor; Rosa Braga-Mele, MD, Cataract Editor; Clara Chan, MD, Cornea Editor; Nathan Radcliffe, MD, Glaucoma Editor; and Vance Thompson, MD, Refractive Editor
For sponsorship opportunities or membership information, contact: ASCRS • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS Opinions expressed in EyeWorld Weekly do not necessarily reflect those of ASCRS. Mention of products or services does not constitute an endorsement by ASCRS.
Click here to view our Legal Notice.
Copyright 2021, EyeWorld News Service, a division of ASCRSMedia. All rights reserved.